



GENOMIC AND PRECISION MEDICINE

PRIMARY CARE

THIRD EDITION

Edited by
SEAN P. DAVID

Series Editors
GEOFFREY S. GINSBURG
HUNTINGTON F. WILLARD



Genomic and Precision Medicine

Primary Care

Third Edition

Edited by

Sean P. David

Stanford University School of Medicine, Stanford, CA, United States

Series Editors


Geoffrey S. Ginsburg

Duke University, Durham, NC, United States

Huntington F. Willard

Marine Biological Laboratory, Woods Hole, MA, United States;

University of Chicago, Chicago, IL, United States



ACADEMIC PRESS

An imprint of Elsevier
elsevier.com

Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
525 B Street, Suite 1800, San Diego, CA 92101-4495, United States
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom

Copyright © 2017 Elsevier Inc. All rights reserved.

Chapter 3 Copyright © 2017 Published by Elsevier Inc.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

British Library Cataloguing-in-Publication Data


A catalogue record for this book is available from the British Library

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

ISBN: 978-0-12-800685-6

For Information on all Academic Press publications
visit our website at <https://www.elsevier.com/books-and-journals>



Working together
to grow libraries in
developing countries

www.elsevier.com • www.bookaid.org

Publisher: Mica Haley

Acquisition Editor: Peter Linsley

Editorial Project Manager: Lisa Eppich

Production Project Manager: Edward Taylor

Designer: Matthew Limbert

Typeset by MPS Limited, Chennai, India

Genomic and Precision Medicine

List of Contributors

- Themistocles L. Assimes** Stanford University School of Medicine, Stanford, CA, United States
- Ehab Billatos** Boston University School of Medicine, Boston, MA, United States
- Maria Esperanza Bregendahl** Stanford University School of Medicine, Stanford, CA, United States
- Maria Chahrour** University of Texas Southwestern Medical Center, Dallas, TX, United States
- Carly Conran** NorthShore University HealthSystem, Evanston, IL, United States
- Damien C. Croteau-Chonka** Harvard Medical School, Boston, MA, United States
- Jose C. Florez** Massachusetts General Hospital, Boston, MA, United States
- Yaron B. Gesthalter** Boston University School of Medicine, Boston, MA, United States
- Susanne B. Haga** Duke University School of Medicine, Durham, NC, United States
- Robert A. Hegele** University of Western Ontario, London, ON, Canada
- J. Kevin Hicks** DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center, Tampa, FL, United States
- Jean Jenkins** National Institutes of Health, National Human Genome Research Institute, Bethesda, MD, United States
- Samuel G. Johnson** Virginia Commonwealth University School of Pharmacy, Washington, DC, United States
- Hasmeena Kathuria** Boston University School of Medicine, Boston, MA, United States
- Roland P. Kuiper** Radboud University Medical Centre, Nijmegen, The Netherlands, Princess Máxima Center for Pediatric Oncology, Nijmegen, The Netherlands
- Matthew B. Lanktree** McMaster University, Hamilton, ON, Canada
- Wennuan Liu** NorthShore University HealthSystem, Evanston, IL, United States
- Paul K. Marcom** Duke University School of Medicine, Durham, NC, United States
- Michael J. McGeachie** Harvard Medical School, Boston, MA, United States
- Howard L. McLeod** DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center, Tampa, FL, United States

Thomas Morgan Novartis Institutes for Biomedical Research, Cambridge, MA, United States

Patricia B. Munroe Queen Mary University of London, London, United Kingdom

Rong Na NorthShore University HealthSystem, Evanston, IL, United States

Lori A. Orlando Duke University, Durham, NC, United States

Latha Palaniappan Stanford University School of Medicine, Stanford, CA, United States

Keyur Patel Toronto General Hospital, Toronto, ON, Canada; Toronto University, Toronto, ON, Canada

Laura Lyman Rodriguez National Institutes of Health, National Human Genome Research Institute, Bethesda, MD, United States

Akanksha Saxena University of Texas Southwestern Medical Center, Dallas, TX, United States

Nicholas A. Shackel University of New South Wales, Sydney, NSW, Australia; Ingham Institute, Liverpool, NSW, Australia; Liverpool Hospital, Liverpool, NSW, Australia

Thomas Tu Universitätsklinikum Heidelberg, Heidelberg, Germany

Miriam S. Udler Massachusetts General Hospital, Boston, MA, United States

Ad Geurts van Kessel Radboud University Medical Centre, Nijmegen, The Netherlands

Helen R. Warren Queen Mary University of London, London, United Kingdom

Scott T. Weiss Harvard Medical School, Boston, MA, United States

Robbert D.A. Weren Radboud University Medical Centre, Nijmegen, The Netherlands

Jianfeng Xu NorthShore University HealthSystem, Evanston, IL, United States

Preface

From the time of completion of the Second Edition of “Genomic and Personalized Medicine” until today, the broad field of genomic medicine has advanced from a period of rapid discovery from genome-wide association studies to—according to the National Human Genome Research Institute’s Eric Green, M.D.—enhancing the understanding of the biology of many diseases and has entered into a phase of advancing the science of medicine with an ultimate endpoint of improving the effectiveness of health care. Although many evidence gaps remain, such as the need to demonstrate clinical validity and clinical utility for most disease associated genetic variants and pharmacogenomics, the potential of “precision medicine” to vastly improve the efficacy of treatments for cancer, neurological diseases, preventive medicine, and reducing health disparities was deemed substantial enough for President Obama to launch the “Precision Medicine Initiative” in his 2015 State-of-the-Union Address. However, as the field of medicine stands poised to advance genomic medicine on many fronts, ensuring that the entire population of patients can benefit from innovations in an evidence-based fashion will rely on partnerships between primary care physicians and clinical genetics professionals. The present text addresses a continuum of domains of genomic medicine that are germane to the primary care of patients and the scope of primary care grounded in family history taking and appropriate referrals, such as the continuing education of all health professionals, what genetic and genomic testing and precision treatments are presently available, and what is on the horizon for a wide range of conditions and population health challenges. It is our hope that primary care providers will, as a result of using this text, develop transdisciplinary thinking and begin to share a common language and sense of partnerships with clinical genetics professionals as we continue to forge this new frontier together for the ultimate goal of improved health, healthcare and more evidence-based, personalized, and patient-centered medicine for the 21st century.

The present, “Primary Care” volume is one of a series of texts tailored to clinicians from a range of medical specialties and academic disciplines. As genomic medicine transitions from a research aspiration to an integral component of personalized health care, the role of primary care physicians and allied health professionals is becoming paramount in the goal of leveraging genomic knowledge to better care for diverse populations. We, therefore, have sought to cover a sample of topics that are essential for building a foundation of general knowledge that we hope will guide primary care clinicians, educators, and

healthcare institutions in advancing translation into practice. The range of topics are not comprehensive, but do provide entry-level content for a range of major health concerns that are equally useful for students, residents, attending physicians, other primary care health professionals, healthcare organizations, and policy makers.

The preface to the previous volume asserted that “We stand at the dawn of a profound change in science and medicine’s predictive nature and in our understanding of the biological underpinnings of health and disease” but noted “grand challenges” to implementation of precision medicine from the potential to exaggerate health disparities to the need for educating the healthcare workforce and developing frameworks for aligning appropriate delivery models with good evidence and appropriate economic incentives. We have attempted to address many of these grand challenges, which align with the National Human Genome Research Institute’s Grand Challenges II (genomics to health) and III (genomics to society) in forward-thinking chapters spanning multiple domains including:

- The role of primary care clinicians in genomic medicine and frameworks for integration with primary care redesign and clinical implementation science
- Genetic screening and diagnostic testing for rare diseases from preconception to neonates and throughout the life span
- Family history and its application to health risk assessment and predictive genetic testing
- Educational strategies for genomic medicine in primary care
- Policy, ethical, and societal considerations
- Current precision medicine treatments and future directions in research for common diseases (cancer, cardiovascular disease, hypertension, diabetes and metabolic syndrome, and autism spectrum disorder)

These topics represent only a fraction of the many diseases and thousands of type of genetic tests and clinical scenarios that are rapidly expanding in number. As Francis Collins envisioned in 2003, with increasing knowledge about the role of genetics in disease risk prediction, “many primary care physicians will become practitioners of genomic medicine, having to explain complex statistical risk information to healthy individuals who are seeking to enhance their chances of staying well. This will require substantial advances in the understanding of genetics by a wide range of clinicians.” This prediction was prescient given the burgeoning research output of genetic studies and the availability of direct-to-consumer genetic testing and diminishing costs of next generation sequencing. We hope this text provides utility to all of us who practice primary care and prevention as vital stakeholders poised to learn together to build a more patient-centered, evidence-based, and personalized healthcare experience for all patients.

Sean P. David,
Huntington F. Willard
and Geoffrey S. Ginsburg

Contents

List of Contributors	xiii
Preface	xv
1. Genomic Medicine in Primary Care	
<i>Samuel G. Johnson</i>	
References	16
2. Overview of Policy, Ethical, and Social Considerations in Genomic and Personalized Medicine	
<i>Susanne B. Haga</i>	
Abbreviations	19
Introduction	20
Issues in Genetics and Genomics Research	20
Under-Represented and Vulnerable Populations	20
Biobanking	22
Returning Research Results	23
Familial Implications	25
Issues Related to Integration of Genomic Medicine Applications in Healthcare	26
Oversight	26
Secondary (Incidental) Findings	27
Direct-to-Consumer (DTC) Genetic Tests	27
Access/Reimbursement	28
Genetic Discrimination	29
Health Professional Education	31
Conclusion	31
References	32
3. Educational Issues and Strategies for Genomic Medicine	
<i>Jean Jenkins and Laura Lyman Rodriguez</i>	
Introduction	45
Gaps in Current Healthcare Professional Literacy	46
Educational Opportunities and Resources to Address Genomic Literacy Gaps	48

What Do Healthcare Providers Need to Understand to Implement Genomic Healthcare?	48
Ethical, Policy, and Social Considerations	53
Resources Available	54
Conclusion	55
Glossary Terms	56
References	56
4. Genetic Testing for Rare and Undiagnosed Diseases	
<i>Thomas Morgan</i>	
Introduction	59
Genotype–Phenotype Causation	60
Genetic Testing Theory	61
Importance of Individual Patient Characteristics in Genetic Test Interpretation	62
Clinical Rationale for Genetic Testing	62
Types of Genetic Testing	62
Potential Indications for Clinical Genome/Exome Sequencing (CGES)	64
General Indications	64
The Acutely Ill Infant	65
Multiple Congenital Anomalies	65
Developmental Delay/Intellectual Disability/Autistic Spectrum Disorders	65
Other Rare Disorders and Syndromes	66
Preimplantation and Prenatal Rare Disease Diagnosis	67
Process of Genetic Testing	68
Undiagnosed Diseases Network	70
Conclusion	71
References	71
5. Health Risk Assessments, Family Health History, and Predictive Genetic/Pharmacogenetic Testing	
<i>Maria Esperanza Bregendahl, Lori A. Orlando and Latha Palaniappan</i>	
Introduction	75
Health Risk Assessments and Family Health History	77
Collecting Family Health History with Electronic Health Record	77
Challenges in Implementing Evidence-Based Guidelines	79
Conclusion	85
References	85
6. Pharmacogenetics and Pharmacogenomics	
<i>J. Kevin Hicks and Howard L. McLeod</i>	
Introduction	89
Molecular Diagnostics for Optimizing Drug Therapy	91

Drug Metabolism	94
Genetic Polymorphisms of Drug Targets	96
Global Health Applications	99
Application in Drug Development	99
Challenges Going Forward	100
Websites of Use	102
References	103

7. Hypertension

Patricia B. Munroe and Helen R. Warren

Abbreviations	109
Introduction	110
Blood Pressure Gene Discovery	111
Large-scale European GWAS Meta-analyses	111
GWAS of Non-European Ancestries	113
Candidate Gene Studies	113
Longitudinal Data, Gene–Lifestyle Interactions and Multi-trait Analyses	114
Bespoke Genotyping Arrays	114
Rare Genetic Variants and BP	115
New BP Genes and Molecular Mechanisms	117
BP Variants and Association with Other Traits and Outcomes	118
Conclusion	123
Acknowledgments	124
References	124

8. Coronary Artery Disease and Myocardial Infarction

Themistocles L. Assimes

Introduction	127
Pathophysiology of CAD and its Major Complications	128
The Genetic Basis of CAD	129
Evidence of Heritability	129
Population Attributable Risk versus Heritability	130
Linkage and Candidate Gene Association Studies	131
The Genome-Wide Association Study (GWAS) Era	131
Heritability Revisited	142
Mechanistic Insights of Newly Identified Loci	142
Relationship of GWAS Susceptibility Loci of CAD with Traditional Risk Factors	142
The Arterial Wall as a Risk Factor for CAD	143
Susceptibility to Plaque Development versus Plaque Rupture and/or Atherothrombosis	143
Pathway Analyses	146
Mendelian Randomization Studies in CAD	148
Genetic Risk Prediction in CAD	150
Gene–Gene and Gene–Environment Interactions	151

Whole Exome Sequencing Association Studies of CAD	153
Conclusion and Future Directions	153
Glossary Terms, Acronyms, Abbreviations	155
References	156
9. Lung Cancer	
<i>Yaron B. Gesthalter, Ehab Billatos and Hasmeena Kathuria</i>	
Introduction	165
Early Diagnosis/Screening of Lung Cancer	166
Smoking, Lung Cancer, and Genetics	166
Identifying Smokers at Risk	167
Future Directions	168
Classification and Prognosis	169
Histological Classification of Lung Tumors and TNM Staging	169
Molecular Classification and Prognostic Value of	
Lung Cancer Genomics	170
Future Directions	171
Pathogenesis and Treatment of Lung Cancer	172
Molecular Alterations in Lung Cancer	172
Oncogenic Pathway Signatures	174
Molecularly Targeted Therapy to Reduce Lung Cancer Mortality	175
Conclusion	176
Glossary	177
References	178
10. Breast Cancer	
<i>Paul K. Marcom</i>	
Introduction	181
Germline Genetic Predisposition	182
Early-stage Breast Cancer Management	184
Development of Molecular Guided Management	184
Defining the Intrinsic Breast Cancer Subtypes	185
Comprehensive Molecular Analysis: The Cancer Genome	
Anatomy Project	186
Gene Expression Profiles for Clinical Management	186
Advanced Metastatic Disease Management	190
Conclusion	191
References	192
11. Colorectal Cancer	
<i>Roland P. Kuiper, Robbert D.A. Weren and Ad Geurts van Kessel</i>	
Abbreviations	195
Introduction	196
Genetics of Colorectal Cancer	196

Genetics of Colorectal-Cancer-Associated Syndromes	197
Nonpolyposis Colorectal Cancer Syndromes	198
Autosomal-Dominant Polyposis-Associated Syndromes	199
Autosomal Recessive Polyposis-Associated Syndromes	201
Other CRC-Associated Syndromes	201
Epimutations and Hereditary Colorectal Cancer	202
Genome-Wide Association Studies	203
Novel Colorectal Cancer Predisposing Genes	203
Perspectives	204
Acknowledgments	205
Glossary Terms	205
References	206

12. Prostate Cancer

Wennuan Liu, Rong Na, Carly Conran and Jianfeng Xu

Introduction	211
Germline Genetics of Prostate Cancer	212
Discoveries of Inherited Variants of Prostate Cancer	212
Translational and Clinical Research	214
Somatic Genetics of Prostate Cancer	215
Major Types of Somatic Genetic Alterations	216
Translational and Clinical Research	219
Epigenetics of Prostate Cancer	220
Epigenetic Mechanisms	220
Translational and Clinical Research	222
Genomic Profiling of RNA in Prostate Cancer	222
Translational and Clinical Research	222
Limitations and Future Directions	223
The Pyramid Model for Personalized Cancer Care	224
Conclusions	225
References	225

13. Asthma

Michael J. McGeachie, Damien C. Croteau-Chonka and Scott T. Weiss

Introduction	231
Asthma: Basic Pathobiology	231
Predisposition (Genetic and Nongenetic) to Asthma	233
Genome-Wide Association Studies of Asthma	233
Asthma Genomics	234
Pharmacogenetics	236
Genomic Prediction in Asthma	239
Conclusions	239
Acknowledgments	239
References	239

14. Diabetes

Miriam S. Udler and Jose C. Florez

Introduction	245
Epidemiology and Genetics	246
Epidemiology of Type 2 Diabetes and its Complications	246
Heritability of Type 2 Diabetes	246
The Search for Genetic Determinants of Type 2 Diabetes	247
Early Studies	247
Genome-Wide Association Studies	248
Exome Array and Next-Generation Sequencing	257
Insights Gained from Genetic Studies in Type 2 Diabetes	264
From Genetic Association to Function	264
Discovery of Novel Pathways	266
Focus on β -Cell Function	267
Hyperglycemia and T2D are not Equivalent	268
Support for Prior Epidemiological Observations	269
Genetic Prediction is not Yet Practical	270
Pharmacogenetics is in Its Infancy	271
Conclusions and Future Directions	272
References	272

15. Metabolic Syndrome

Matthew B. Lanktree and Robert A. Hegele

Introduction	283
Defining Metabolic Syndrome	284
Pathophysiology of Metabolic Syndrome	285
Heritability of Metabolic Syndrome	286
Monogenic Models of Metabolic Syndrome	287
Lipodystrophy	287
Monogenic Diseases of Obesity and Insulin Resistance	289
Genetics of Common Metabolic Syndrome	291
Linkage Analysis	291
Candidate Gene-Association Studies	291
Genome-Wide Association Studies	292
Risk-Score Analysis	293
Finding the Missing Heritability	293
The "Thrifty-Gene" Hypothesis	295
Clinical Implications to Genetic Findings in Metabolic Syndrome	295
Conclusion	295
Acknowledgments	296
Glossary	296
References	296

16. Autism Spectrum Disorder*Akanksha Saxena and Maria Chahrour*

Introduction	301
Clinical Overview	302
The Complex Genetics of ASD	302
Chromosomal Abnormalities and Copy Number Variants	303
Syndromic Genes	305
Rare Single Nucleotide Variants, <i>De Novo</i> and Inherited	307
Genomics and Diagnosis in ASD	310
Conclusion	312
References	312

17. Viral Hepatitis*Thomas Tu, Keyur Patel and Nicholas A. Shackel*

Abbreviations	317
Introduction	318
The Hepatitis Viruses	318
Genetic Predisposition to Viral Hepatitis	318
Acute Viral Hepatitis	321
Factors Affecting the Postexposure Clinical Outcome of Hepatitis Infection	323
Postexposure Outcomes in HAV Infection	323
Postexposure Outcomes in HBV Infection	323
Postexposure Outcomes in HCV Infection	324
Postexposure Outcomes in HDV and HEV Infections	325
Chronic Hepatitis	325
Factors Affecting Liver Disease Progression	326
Disease Progression in Chronic HBV Infection	328
Disease Progression in Chronic HCV Infection	329
Hepatitis Virus–Associated HCC	329
Treatment of Hepatitis Virus Infection	331
Treatment of Chronic HBV Infection	331
Treatment of Chronic HCV Infection	332
Future Impact of Genomics and Personalized Medicine	332
Conclusion	333
References	334

Index	341
--------------	-----

Chapter 1

Genomic Medicine in Primary Care

Samuel G. Johnson

Virginia Commonwealth University School of Pharmacy, Washington, DC, United States

Chapter Outline

References

16

The last two decades has seen unprecedented genomic discovery and major clinical advances in the management of common diseases including cardiovascular disease and cancer [1]. In the fast-paced practice environment with limited time to stay current with new medical literature, many primary care physicians may not highly prioritize continuing education about genomic medicine in particular. Moreover, many primary care physicians express little confidence in their ability to make clinical decisions when genetic or genomic information is involved. This challenge is not unique to primary care; as new medical discoveries often outpace an individual specialist practitioner’s ability to master it as well. Even so, primary care physicians now have better resources to help them incorporate new medical knowledge, including genomic medicine, into practice [1]. Emphasis on generalist practice principles, especially the value of maintaining a broad knowledge base, spurs many to stay current with new literature while prioritizing what is most important to their patients’ health. This may manifest as reliance on clinical practice guidelines in addition to cultivation of networks of trusted colleagues (through both informal “curbside” and formal consultations). With the rise of genomic medicine, these networks will increasingly include geneticists, genetic counselors, informaticists, and pharmacists.

Knowledge learned through such patient-centered interactions contributes to innovation in systems design that streamlines management of complex medical information. Such clinical decision support systems are increasingly being

introduced into electronic health records across North America, and provide just-in-time alerts to front-line clinicians for many issues; including, adverse drug interactions or overdue health maintenance interventions. Efforts are already underway within leading health systems to incorporate genomic data into the electronic records in a similar fashion, in order to create systems to help manage large quantities of genomic information [2]. Since it is also important to prepare the future primary care physician workforce for this innovation, primary care residencies may also include more focus on genomics education and training [3].

The potential benefits of genomic medicine are many and include improved disease-risk assessment as well as precise selection of drug therapy. Potential detriments include provider and patient anxiety, the unnecessary and expensive tests and procedures that might follow from a genomic result, and many scenarios where current scientific understanding fails to ascertain actionable results [4]. Further, despite rapid advances in understanding the genetic architecture of many diseases, translational research that demonstrates outcome improvement from this knowledge has lagged. The full risk–benefit ratio is thus unknown for almost all genomic tests, particularly for long-term clinical outcomes. Since primary care practice fosters a culture of evidence-based medicine that seeks to maximize health benefits and minimize unnecessary harms to patients, primary care physicians may be reluctant to integrate genomics into clinical practice. While certain genomic tests have been better studied than others—for example, variants in the *BRCA1/2* genes which have proven implications for the risk assessment and management of hereditary breast and ovarian cancer, and pharmacogenetic considerations for efficacy and safety on the labels of more than 130 medications including clopidogrel, warfarin, and citalopram [5]—developing an evidence base for most genomic tests comparable to what is known about *BRCA* testing, for example, will require decades of research in large populations. Pending such research; however, primary care physicians may still make clinical decisions to benefit individual patients despite an underdeveloped evidence base.

Upon the completion of the Human Genome Project in 2003 and on the 50th anniversary of Watson and Crick’s landmark discovery of the double-helical nature of DNA [6], then National Human Genome Research Institute Director Francis Collins, M.D., Ph.D. (now Director for the National Institutes of Health) envisioned a blueprint for research in the genomic era and a series of Grand Challenges (Table 1.1) to guide the translation of genomic knowledge to enhance understanding of biological mechanisms of disease (Grand Challenge I), genomics to health (Grand Challenge II), and genomics to society (Grand Challenge III). Rapid advances in Grand Challenge I rapidly ensued over the following decade. From 2005 to 2012, the number of genome-wide association studies (GWAS) increased exponentially with 1,350 publications in 2012 [7]. More than 150 GWAS markers have been associated with common diseases including cancer, type 2 diabetes mellitus, dyslipidemia, multiple sclerosis, nicotine dependence, and psoriasis, there are also dozens of GWAS hits associated